Enhance your summer wellness with iHerb's range of trusted vitamins and supplements
If you want to shop the way that millions of others do, shop at iHerb – a treasure trove of vitamins, supplements, and so much more, which is trusted by over 12.5 million customers worldwide already. The company was founded in California in 1996 and has continued to rise in popularity over the last few decades.
iHerb offers such a great experience to customers by mastering a few stand-out things. First is the retailer's vast catalog of over 50,000 products, sourced from more than 1,800 reputable brands (including a wide range of vitamins, minerals, supplements, sports nutrition, beauty and personal care items, health foods and much more). Next up is iHerb's commitment to excellent value – by sourcing products directly, shipping from climate-controlled warehouses, and fast and affordable shipping to over 180 countries, with free shipping to the UK for orders over 35 pounds.
Just some of iHerb's best-selling brands include Advanced Clinicals, Medix 5.5, Beauty of Joseon, PanOxyl, Maui Babe, Cosrx and Anua.
So whether you know your retinol from your retinal, need a complete education on an antioxidant that works for you, or have recently transitioned to a vegan diet and need to change up your supplements, iHerb have got you covered.
Here's some of iHerb's stand-out products...
In order to keep hair, skin, nails, joints and bones healthy as we age, collagen is one of the best supplements that we can take. When paired with hyaluronic acid and vitamin C, we've got a dream combo. This CollagenUP powder contains both type I and type III collagen, which are two of the main types, responsible for contributions towards bone, skin and ligament structure, along with muscles, arteries and organs.
MaryRuth's liquid multivitamins is certainly not a new product, but is one that has been loved for years, with good reason. Each bottle includes all eight B vitamins, including 10,000 mcg biotin magnesium biotinate, a unique form of biotin that is 40 times more soluble than D-biotin, along with vitamin A, vitamin D3 and chromium picolinate. Inside is also Lustriva, which has been clinically shown to help hair grow thicker in just a few weeks, and has been found to soften fine lines and wrinkles.
If you haven't got on the ashwagandha train yet, this is your sign. Ashwagandha is an incredibly powerful adaptogen that works by supporting normal cortisol levels and can promote a healthy response to stress, aid your immune system, improve your sleep quality, benefit athletic performance and so much more. Swanson's capsules contain an impactful 450mg of pure ashwagandha root and plant-based ingredients, that haven't undergone any unnecessary processing.
For just over £10 you can get a whopping 454g of brightening vitamin C cream, which is incredibly good value. Formulated with powerful ingredients of vitamin C and E, green tea and nourishing coconut and jojoba oils, this spa sized brightening cream is a summer staple. The cream is formulated to brighten age spots, refine discolouration and soften the skin, and is clinically, dermatologically and allergy tested.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
As class action trial looms, Meta and Flo could face 'mind-boggling' damages
July 15 (Reuters) - It's hard to imagine more intimate queries than those that fertility tracking app Flo allegedly asked its users. Among them: When was your last period? How often do you have sex? Masturbate? Do you get yeast infections? As app maker Flo Health and co-defendant Meta are set to face a class action trial in San Francisco federal court next week for allegedly violating the privacy of millions of Flo users, the question now is whether the companies will cut a deal or risk what Flo on appeal, opens new tab termed "mind-boggling" damages. Litigators sometimes bandy about the phrase 'bet-the-company case,' but this could be the real thing. Facebook parent Meta is defending against claims of violating the California Invasion of Privacy Act, which carries statutory penalties of $5,000 per violation. That would add up to at least $190 billion in damages if, as plaintiffs have previously suggested, opens new tab, there are 38 million class members. If each app entry is treated as a separate violation, total damages could be quadrillions of dollars — "a sum so large it may as well be infinite," as Flo put it. A spokesperson for Meta, which is represented by outside counsel from Latham & Watkins and Gibson, Dunn & Crutcher, said the plaintiffs' claims against the company "are simply false, and we are confident that the evidence at trial will demonstrate the realities." Flo, represented by Dechert, separately is dealing with claims including violations of California's Confidentiality of Medical Information Act, which carries penalties of $1,000 per violation. A spokesperson for the London-based, privately held company said Flo "is committed to protecting the privacy of its users, and any allegation otherwise has no merit." The companies have argued that Flo's privacy disclosures gave users notice of the alleged misconduct and that they impliedly consented, that the shared data did not contain personally identifying information and that Meta never 'intended' to intercept communications. According to the Meta spokesperson, the company does 'not want health or other sensitive information' and its terms 'prohibit developers from sending any.' Google, which was also named in the suit, reached a settlement in principle last week on as-yet undisclosed terms. A Google spokesperson did not respond to my request for comment. Given the risk of outsized verdicts (even those that don't involve 16 figures), class actions rarely go to trial. For example, Google last month took a chance on one involving cellular phone data, only to be hit with a $314 million verdict by a California jury on July 1. The Flo plaintiffs invoke California's 1967 invasion of privacy law, a Cold War relic that makes it illegal to covertly eavesdrop or record telephone conversations. As I previously wrote, the cause of action has enjoyed a resurgence of late among plaintiffs' lawyers, especially in connection with the use of chatbots, tracking pixels and other data analytics software. The Flo jury trial, set for July 21 before U.S. District Judge James Donato, looms as current and former Meta leaders face an $8 billion shareholder suit in Delaware that kicks off Wednesday. The shareholders allege Meta executives violated a 2012 agreement between Facebook and the Federal Trade Commission to protect users' data, my Reuters colleague Tom Hals reports. The Flo class action also has its roots in an FTC case. The agency sued Flo, opens new tab after The Wall Street Journal in 2019 reported that it was able to intercept identifying health information about Flo users transmitted by the app to Facebook. The FTC's 2021 settlement required Flo to obtain users' consent before sharing their health information and to notify affected women about the disclosure. According to the follow-on class action, opens new tab, which covers all Flo app users nationwide from Nov. 1, 2016, to Feb. 28, 2019, plus a California subclass, Flo integrated code from Meta and Google's software development kits, which are used for data analytics, into its app. That allegedly allowed the companies to review personal information on users' menstrual cycles, sex lives and pregnancies, despite promises by Flo that the data would remain confidential. The third parties were "were free to use this data for their own purposes," including marketing and advertising, the complaint alleges. "If Plaintiff and Class members had known that Flo Health would share their intimate health data, they would not have used the Flo App." Plaintiffs' lawyers from Labaton Keller Sucharow; Lowey Dannenberg and Spector Roseman & Kodroff did not respond to requests for comment. Donato certified the class in May, writing, opens new tab that the 'loss of control over one's personal information' is a concrete harm, "whether from stealing access to a personal diary in 1916 or obtaining user information in a healthcare app in 2016.' The decision prompted an interlocutory appeal, opens new tab in June by Flo to the 9th U.S. Circuit Court of Appeals. Flo argued that Donato wrongly held that the company's class action waiver was unenforceable. The judge deemed the provision unconscionable because it was buried in Flo's terms of service. Flo also argued that the company's use of the software development kits is 'a practice as unremarkable as it is widespread,' and that it disclosed using the kits in its privacy policy and terms of service. Flo also said the transmitted data was de-identified, consisting of alphanumeric strings corresponding to the device on which the app was used. The appeals court in six-sentence order, opens new tab on June 17 denied Flo's petition and declined to stay the lower court proceedings. 'Cases of this magnitude almost never proceed to trial,' Flo noted in its appeal, describing the 'hydraulic pressure' to settle. I can only imagine. But if it does indeed go to trial, all I can say is, pass the popcorn.
Daily Mail
an hour ago
- Daily Mail
Legendary bodybuilder Ronnie Coleman reveals 13-year-old daughter stopped him dying from sepsis
Bodybuilding legend Ronnie Coleman has revealed how his teenage daughter helped save his life as he opened up on his severe health battle. Coleman's family announced earlier this month that the 61-year-old had been ' admitted to hospital' before later revealing he had suffered an 'infection in his bloodstream'. On Tuesday, the former Mr. Olympia spoke out for the first time since being hospitalized with sepsis - a life-threatening medical emergency that arises when the body reacts improperly to infection. The Louisiana native revealed just how close he came to losing that battle, if not for his 13-year-old daughter. 'Man, let me tell you, these past few weeks have been some of the toughest of my life,' he said in a video shared to his Instagram. 'Your boy was hit with sepsis, and it nearly killed me. Had it not been for my 13-year-old daughter, it probably would have.' View this post on Instagram A post shared by Ronnie Coleman (@ronniecoleman8) Coleman didn't expand on how his daughter helped prevent the disease from killing him. The bodybuilder has six daughters - two from his previous marriage and four he shares with his wife and personal trainer Susan Williamson. 'Y'all know me, I've been faced with battles in my life, but nothing like this,' he continued. 'I'm still here because the grace of God still wants me to be here. The support I get from all of y'all, that all helps out a lot.' Coleman went on to announce that his horrific ordeal had inspired him to support the Sepsis Alliance ro raise awareness. Concerns over his health initially arose after he was forced to postpone a scheduled trip to the UK last week. In an Instagram post, Coleman broke news of his illness as he wrote: 'Hey guys, I hate to break it to y'all, but I won't be able to make it out to the UK this week like I planned. Unfortunately, I had a medical emergency and had to stick around here in the U.S. for treatment. 'But don't worry… I'm in great hands, getting the best care, and I'm staying strong through it all. I'll be back and better than ever, and I can't wait to get out there and see you all real soon!' His family later revealed that Coleman would require emergency surgery after doctors discovered an 'underlying health issue' during testing to identify the source of the infection. Coleman holds the, joint, all-time record for most Mr. Olympia titles at eight. He's also previously won 26 International Fitness and Bodybuilding Federation (IFBB) titles and retired back in 2007 after his reign as Mr. Olympia came to an end.
Reuters
3 hours ago
- Reuters
Hims & Hers hit with investor lawsuits after Novo ends Wegovy partnership
July 15 (Reuters) - Telehealth company Hims & Hers (HIMS.N), opens new tab is facing a growing number of U.S. investor lawsuits after Novo Nordisk's ( opens new tab decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug through the platform sent shares plunging. A group of shareholders sued Hims on Monday in federal court in San Francisco, accusing its board and senior executives of making false and misleading statements about its financial condition and operations. The case was filed as a so-called derivative lawsuit on behalf of the company. The lawsuit follows two securities class actions filed by Hims investors in the same court last month, seeking damages over the drop in stock price after Novo in late June ended what the companies had initially described as a long-term collaboration designed to make obesity care and treatment more affordable and accessible. Hims, Novo and the lawyers who filed Monday's lawsuit did not immediately respond to requests for comment. Danish drugmaker Novo is not a defendant in the lawsuits. Founded in 2017, San Francisco-based Hims provides health and wellness products focused on weight loss, sexual and mental health and hair loss. Novo on June 23 said it was ending their partnership that began in late April, citing Hims' alleged improper marketing and sales of Wegovy copies. Novo accused Hims of 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' Hims CEO Andrew Dudum responded, opens new tab in a post on X that day that accused Novo management of misleading the public and making anticompetitive demands 'that infringe on the independent decision making of providers and limit patient choice.' Hims shares fell $22.24, or over 34%, after Novo's announcement, declining from $64.22 per share on June 20 to close at $41.98 per share on June 23. The stock closed on Monday at $52.03 a share. The tight supply of Wegovy in the United States had allowed Hims and others to sell cheaper, compounded versions of the drug, known chemically as semaglutide. The U.S. Food and Drug Administration in February removed Wegovy from the agency's shortage list. Hims said the decision meant it could not guarantee continued sales of compounded semaglutide. The case is Steve Jones v. Andrew Dudum, U.S. District Court, Northern District of California, No. 3:25-cv-05866-AGT. For plaintiff: Shane Rowley of Rowley Law PLLC, and Francis "Casey" Flynn Jr. of Law Office of Francis J. Flynn Jr For defendants: No appearances yet Read more: Novo, Hims & Hers engage in war of words after Wegovy deal falls apart US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list Novo Nordisk to sell Wegovy through telehealth firms to cash-paying US customers
